Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • Daily Feed
  • Analyst Insights & IR
  • Disclosures
    • Semiconductors
    • Energy
    • Robotics
    • Bio & Healthcare
  • Toggle search form

[Disclosure] Alteogen (196170) Sets November 21 as Record Date to Determine Voting Rights for Extraordinary General Meeting

Posted on November 6, 2025July 11, 2026 By K-STOCK Editor No Comments on [Disclosure] Alteogen (196170) Sets November 21 as Record Date to Determine Voting Rights for Extraordinary General Meeting

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-11-06

Disclosure Type: Setting of Shareholder Register Closing Period or Record Date

💡 3-Second Summary

Alteogen has officially designated November 21, 2025, as the ‘Record Date’ to finalize the list of shareholders eligible to vote at the upcoming Extraordinary General Meeting of Shareholders.

📊 1. [Summary of Core Disclosure Content and Key Figures]

  • Record Date: November 21, 2025
  • Share Transfer Suspension Period: Not Applicable (Only the record date is set, without closing the shareholder register)
  • Purpose of Setting: Finalizing eligible shareholders for holding an Extraordinary General Meeting of Shareholders (EGM)
  • Board Decision Date: November 06, 2025
  • Legal Basis: Pursuant to Article 354 of the Commercial Act and Article 17 of the Company’s Articles of Incorporation (Closing of Shareholder Register and Record Date)

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This disclosure represents a routine administrative prerequisite to smoothly host a major upcoming corporate event—specifically, the EGM intended for the KOSPI market relocation. It is an operational announcement to define voting eligibility and does not introduce immediate changes to financial metrics or corporate Fundamental.

While it does not function as a market-moving short-term event, it carries substantial administrative importance for investors wishing to participate in the critical voting process regarding Alteogen’s market relocation. Shareholders must hold the stock on the specified record date of November 21 to secure their voting rights, meaning their actual stock purchase should be completed two business days prior to the record date due to standard settlement cycles.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen is initiating the necessary administrative steps to organize the high-stakes EGM where the KOSDAQ delisting and KOSPI move will be decided. Given that minority and general investors represent a massive 74.59% stake in the company, every single vote counts toward shaping the company’s future listing venue. For international and domestic investors aiming to cast their ballots regarding this migration, verifying ownership eligibility by the established November 21 record date will be the very first mandatory checkpoint.

📢 Disclaimer and Source Information

Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided solely for information and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.

🐂
BULLS
VS
🐻
BEARS

🔥 Bulls vs Bears, drop your analysis in the comments!

Disclosures, Bio & Healthcare

Post navigation

Previous Post: [Disclosure] Alteogen (196170) Decides to Table Agenda for Delisting Approval to Relist on KOSPI Market
Next Post: [Disclosure] Alteogen (196170) to Hold EGM on December 8 for KOSPI Relocation and E-Voting Implementation

Related Posts

[Disclosure] Alteogen (196170) Announces KRW 155B Third-Party Placed Paid-in Capital Increase via Redeemable Convertible Preferred Shares for Manufacturing Plant Construction Disclosures
[Disclosure] Alteogen (196170) Signs Exclusive License Agreement with AstraZeneca Subsidiary for ALT-B4 Valued up to USD 600M (KRW 872.9B) Disclosures
[Disclosure] Alteogen (196170) Scores Huge Win: Eylea Biosimilar ‘Eyzanfy’ Secures Official MFDS Marketing Approval in South Korea Disclosures
[Disclosure] Alteogen (196170) to Hold AGM on March 31; Agenda Includes Re-appointment of CEO Park Soon-jae and Appointment of VP Choi Sang-rak as Inside Director Disclosures
[Disclosure] Alteogen (196170) Designated as Short-Selling Overheated Stock; Short-Selling Banned on May 15 Disclosures
[Disclosure] Alteogen (196170) to List 40,820 Additional Common Shares Following Executive Stock Option Exercises Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Hana Micron (067310) Lifted from Investment Warning Stock Status; Reclassified to Investment Caution on June 9 with Re-designation WarningJuly 8, 2026
  • [Discount Reversal via ADR Listing and Entry into an HBM-Led Super Cycle: SK hynix 000660]July 7, 2026
  • [Discount Narrowing via ADR Listing Momentum and Capital Allocation Diversification: SK Square 402340]July 7, 2026
  • Gaon Cable (000500): Structural Re-rating Driven by North American Infrastructure Expansion and AI Data Center Demand ShocksJuly 7, 2026
  • Hugel (145020): Passing the Trough with Q2 Earnings Surprise and Accelerated U.S. Direct Sales DeploymentJuly 7, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme